Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers

• Published in: Biomaterials 2017-03, Vol.121, p.15-27
• Main Authors: Shukla, Sourabh, Myers, Jay T, Woods, Sarah E, Gong, Xingjian, Czapar, Anna E, Commandeur, Ulrich, Huang, Alex Y, Levine, Alan, Steinmetz, Nicole F
• Format: Article
• Language: English
• Subjects: Adaptive Immunity - immunology; Advanced Basic Science; Animals; Antigen delivery; Biological Transport, Active - immunology; Cancer vaccine; Cancer Vaccines - immunology; Cell Line, Tumor; Dentistry; HER2; Humans; Mice; Neoplasms, Experimental - immunology; Oncogenic Viruses - immunology; Peptide vaccine; Plant Viruses - immunology; Receptor, ErbB-2 - immunology; Subcellular Fractions - immunology; Viral nanoparticles; Virion - immunology
• ISSN: 0142-9612; 1878-5905; 1878-5905
• DOI: 10.1016/j.biomaterials.2016.12.030

Abstract Cancer vaccines are designed to elicit an endogenous adaptive immune response that can successfully recognize and eliminate residual or recurring tumors. Such approaches can potentially overcome shortcomings of passive immunotherapies by generating long-lived therapeutic effects and immune memory while limiting systemic toxicities. A critical determinant of vaccine efficacy is efficient transport and delivery of tumor-associated antigens to professional antigen presenting cells (APCs). Plant viral nanoparticles (VNPs) with natural tropism for APCs and a high payload carrying capacity may be particularly effective vaccine carriers. The applicability of VNP platform technologies is governed by stringent structure-function relationships. We compare two distinct VNP platforms: icosahedral cowpea mosaic virus (CPMV) and filamentous potato virus X (PVX). Specifically, we evaluate in vivo capabilities of engineered VNPs delivering human epidermal growth factor receptor 2 (HER2) epitopes for therapy and prophylaxis of HER2+ malignancies. Our results corroborate the structure-function relationship where icosahedral CPMV particles showed significantly enhanced lymph node transport and retention, and greater uptake by/activation of APCs compared to filamentous PVX particles. These enhanced immune cell interactions and transport properties resulted in elevated HER2-specific antibody titers raised by CPMV- vs. PVX-based peptide vaccine carriers. The ‘synthetic virology’ field is rapidly expanding with numerous platforms undergoing development and preclinical testing; our studies highlight the need for systematic studies to define rules guiding the design and rational choice of platform, in the context of peptide-vaccine display technologies.